^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

Calcineurin inhibitor

22h
Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD (clinicaltrials.gov)
P4, N=30, Not yet recruiting, Peking University People's Hospital | N=118 --> 30
Enrollment change
|
prednisone • cyclosporine
3d
Clinically Amyopathic Dermatomyositis: Epidemiology, Clinical Presentation, Pathophysiology, Treatment, and Prognosis: A Systematic Review. (PubMed, Rheumatol Ther)
CADM is a serious, complex disease with a distinct clinical and serological profile, requiring further conceptual refinement and multicenter studies to better characterize this DM phenotype.
Review • Journal
|
IFIH1 (Interferon Induced With Helicase C Domain 1) • CRP (C-reactive protein)
|
Rituxan (rituximab) • cyclophosphamide • cyclosporine
7d
Trial completion
|
everolimus • cyclosporin A microemulsion
10d
Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction (clinicaltrials.gov)
P4, N=48, Recruiting, University of Alabama at Birmingham | Not yet recruiting --> Recruiting
Enrollment open
11d
STELLA: a spatial transcriptomics framework for microenvironment decoding using dynamic graph neural networks. (PubMed, Sci China Life Sci)
It also identified immune aggregation areas in intestinal tissues and implicated the cyclosporin A signaling pathway in the FDCSP+ S4 stromal cell microenvironment. Additionally, STELLA detected that PERIOSTIN and MHC-II form a central-peripheral bidirectional regulatory network with complementary directionality in the mouse striatum. Finally, it analyzed the transition from WSN-mediated early stress response to reaEGC-mediated tissue reconstruction during axolotl brain regeneration.
Journal
|
POSTN (Periostin)
|
cyclosporin A microemulsion
13d
Ionomycin enhances radiosensitivity in breast cancer through reactive oxygen species generation and mitochondrial permeability transition pore opening. (PubMed, Med Gas Res)
The reduction in cell viability induced by ionomycin combined with radiotherapy was significantly reversed by N-acetyl-L-cysteine (a reactive oxygen species scavenger) and cyclosporine A (mitochondrial permeability transition pore channel inhibitor)...This research indicates that ionomycin may function as an effective radiosensitizer, therefore enhancing the efficacy of radiotherapy in the treatment of breast cancer. JOURNAL/mgres/04.03/01612956-990000000-00102/inline-graphic1/v/2026-06-06T092751Z/r/image-tiff.
Journal
|
CASP3 (Caspase 3)
|
cyclosporin A microemulsion
14d
T-cell large granular lymphocyte leukaemia with pure red cell aplasia harbouring a somatic STAT3 P715L mutation. (PubMed, BMJ Case Rep)
The patient responded to ciclosporin therapy with gradual haematological improvement and became transfusion-independent within 6 months. This case highlights the importance of molecular profiling in T-LGLL presentations and expands the known mutational spectrum of STAT3 It also raises the possibility that non-SH2 (Src homology 2) domain STAT3 mutations may contribute to disease pathogenesis and influence treatment response in T-LGLL.
Journal
|
CD8 (cluster of differentiation 8) • STAT3 (Signal Transducer And Activator Of Transcription 3)
|
STAT3 mutation
|
cyclosporine
18d
Colon-targeted mucin/cyclosporine A co-loaded microspheres synergistically ameliorate ulcerative colitis via immunosuppression and mucosal barrier repair. (PubMed, Colloids Surf B Biointerfaces)
The combination of CyA-mediated immunosuppression and mucin-mediated mucosal repair achieved superior efficacy, with excellent biosafety. This colon-targeted co-delivery strategy offers a promising approach for more effective and safer UC therapy.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta) • TJP1 (Tight Junction Protein 1) • OCLN (Occludin)
|
cyclosporin A microemulsion
21d
Cyclosporine in hematological disorders: mechanisms, clinical practice and emerging advances. (PubMed, Ann Hematol)
Cyclosporine A (CsA) functions as a calcineurin inhibitor that perturbs T cell activation via calcineurin-nuclear factor of activated T cells (CaN-NFAT) signaling inhibitors, establishing its central role in hematological therapeutics. The manuscript further elaborates on pharmacological synergies between CsA and novel targeted agents including eltrombopag, ruxolitinib, and immune checkpoint inhibitors, while evaluating its capacity to surmount chemotherapeutic resistance and function as a bridging modality to CAR-T cell infusion. Lastly, we propose tiered management protocols for dose-limiting toxicities (nephrotoxicity and hypertension) and highlight emerging research frontiers in nanoformulation and artificial intelligence-guided therapeutic drug monitoring.
Review • Journal • IO biomarker
|
STAT3 (Signal Transducer And Activator Of Transcription 3) • NFATC1 (Nuclear Factor Of Activated T Cells 1)
|
STAT3 mutation
|
Jakafi (ruxolitinib) • Promacta (eltrombopag) • cyclosporin A microemulsion
22d
New P4 trial
|
Gazyva (obinutuzumab)